Department of Health and Human Services$1.1M obligationsEnds Dec 18, 2021
Federal contract award
HHSN26100008
IGF::OT::IGF ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541712 |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | HHSN261201200034I |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $1.6M |
| Current contract value | $1.6M |
| Potential contract value / ceiling | $1.7M |
| Start date | Aug 1, 2015 |
| Current end date | Jul 31, 2022 |
| Potential end date | Jul 31, 2022 |
| Latest award activity | Dec 12, 2024 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 12, 2024 | P00007 | $-598 | ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.